Literature DB >> 19812502

Association of renal damage with cardiovascular diseases is independent of individual cardiovascular risk profile in hypertension: data from the Italy - Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease study.

Sebastiano Sciarretta1, Valentina Valenti, Giuliano Tocci, Roberto Pontremoli, Enrico Agabiti Rosei, Ettore Ambrosioni, Vittorio Costa, Gastone Leonetti, Achille Cesare Pessina, Bruno Trimarco, Diana Chin, Francesco Paneni, Giacomo Deferrari, Andrea Ferrucci, Massimo Volpe.   

Abstract

OBJECTIVES: In the past years, several risk charts have been created to increase the accuracy of cardiovascular risk stratification. The most widely used and validated algorithms do not included target organ damage as risk prediction. The aim of the present study was to evaluate whether preclinical renal damage is associated with cardiovascular diseases independently of individual risk profile assessed by risk charts.
METHODS: The study population was that of Italy-Developing Education and awareness on MicroAlbuminuria in patients with hypertensive Disease, a large observational study conducted on hypertensive patients in Italy. The Framingham Risk Score (FRS), Systematic COronary Risk Estimation (SCORE) and Progetto Cuore Risk Score (Progetto Cuore RS) were computed in each eligible patient. Chronic kidney disease was defined by the presence of albuminuria or by a reduction of glomerular filtration rate.
RESULTS: Study participants were categorized to have low, medium and high risk according to the tertiles of the three charts. Prevalence of total cardiovascular diseases progressively and significantly increased according to the degrees of risk assessed by the three charts, the highest prevalence being in participants with a high-risk profile (both high and medium vs. low risk <0.01 for FRS, SCORE and Progetto Cuore RS). The presence of chronic kidney disease was associated with total cardiovascular diseases, independently of FRS (odds ratio 1.64, 95% confidence interval 1.33-2.02, P < 0.001), SCORE (odds ratio 1.55, 95% confidence interval 1.21-1.98, P < 0.001) and Progetto Cuore RS (odds ratio 1.59, 95% confidence interval 1.22-2.07, P < 0.001). Moreover, inclusion of renal damage in the logistic model significantly increased the accuracy of the FRS (P < 0.05), SCORE (P < 0.01) and Progetto Cuore RS (P < 0.01) to identify patients with overt cardiovascular diseases.
CONCLUSION: Identification of patients with preclinical renal damage should be encouraged in the hypertension cardiovascular risk stratification setting in order to achieve a more accurate individual risk computation. The presence of renal damage could improve cardiovascular risk prediction over the widely used risk stratification charts.

Entities:  

Mesh:

Year:  2010        PMID: 19812502     DOI: 10.1097/HJH.0b013e3283326718

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  11 in total

1.  Increased urine semaphorin-3A is associated with renal damage in hypertensive patients with chronic kidney disease: a nested case-control study.

Authors:  Francesca Viazzi; Ganesan Ramesh; Calpurnia Jayakumar; Giovanna Leoncini; Debora Garneri; Roberto Pontremoli
Journal:  J Nephrol       Date:  2014-04-23       Impact factor: 3.902

Review 2.  Chronic kidney disease in the hypertensive patient: an overview of the I-DEMAND study.

Authors:  Giovanna Leoncini; Francesca Viazzi; Enrico Agabiti Rosei; Ettore Ambrosioni; Francesco V Costa; Gastone Leonetti; Achille C Pessina; Bruno Trimarco; Massimo Volpe; Giacomo Deferrari; Roberto Pontremoli
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-03-01

3.  Target organ damage in a population at intermediate cardiovascular risk, with adjunctive major risk factors: CArdiovascular PREvention Sacco Study (CAPRESS).

Authors:  Francesca Perego; Elio Renesto; Massimo Arquati; Luciana Scandiani; Chiara Cogliati; Daniela Torzillo; Luca Zocchi; Giovanni Casazza; Piergiorgio Duca; Saverio Chirchiglia; Gemma Lacaita; Mauro Panteghini; Michele Cortellaro
Journal:  Intern Emerg Med       Date:  2010-12-17       Impact factor: 3.397

Review 4.  Management of children after renal transplantation: highlights for general pediatricians.

Authors:  Keith K Lau; Lucy Giglia; Howard Chan; Anthony K Chan
Journal:  Transl Pediatr       Date:  2012-07

Review 5.  Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.

Authors:  Giuliano Tocci; Barbara Citoni; Vivianne Presta; Giovanna Leoncini; Francesca Viazzi; Barbara Bonino; Massimo Volpe; Roberto Pontremoli
Journal:  Intern Emerg Med       Date:  2019-12-21       Impact factor: 3.397

Review 6.  Identification and management of albuminuria in the primary care setting.

Authors:  Louis Kuritzky; Robert Toto; Peter Van Buren
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-02-01       Impact factor: 3.738

7.  Alternative splicing events is not a key event for gene expression regulation in uremia.

Authors:  Marion Sallée; Michel Fontès; Laurence Louis; Claire Cérini; Philippe Brunet; Stéphane Burtey
Journal:  PLoS One       Date:  2013-12-16       Impact factor: 3.240

8.  No association between cyclosporine levels and dyslipidemia?

Authors:  Guido Filler
Journal:  Nephrourol Mon       Date:  2014-01-13

9.  Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation.

Authors:  Luis Rodriguez-Padial; Finn Akerström; María G Barderas; Fernando Vivanco; Miguel A Arias; Julian Segura; Luis M Ruilope
Journal:  Diseases       Date:  2017-12-08

10.  Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease.

Authors:  Nathalie Neirynck; Sunny Eloot; Griet Glorieux; Daniela V Barreto; Fellype C Barreto; Sophie Liabeuf; Aurélie Lenglet; Horst D Lemke; Ziad A Massy; Raymond Vanholder
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.